Literature DB >> 35084584

Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study.

Sanne Werner Møller Andersen1, Camilla Ottesen2, Klaus Gotfredsen2, Simon Storgård Jensen3,4, Thomas Kofod3, Morten Schiodt3,5.   

Abstract

PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.
METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.
RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.
CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antiresorptive agents; Cancer; Dental implant; Prosthodontics

Year:  2022        PMID: 35084584     DOI: 10.1007/s10006-022-01042-5

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  37 in total

Review 1.  Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.

Authors:  Ourania Nicolatou-Galitis; Morten Schiødt; Rui Amaral Mendes; Carla Ripamonti; Sally Hope; Lawrence Drudge-Coates; Daniela Niepel; Tim Van den Wyngaert
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2018-10-09

2.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

3.  Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system.

Authors:  Morten Schiodt; Jesper Reibel; Peter Oturai; Thomas Kofod
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-11-15

4.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  Aust Endod J       Date:  2009-12       Impact factor: 1.659

Review 5.  Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.

Authors:  Sven Otto; Christoph Pautke; Tim Van den Wyngaert; Daniela Niepel; Morten Schiødt
Journal:  Cancer Treat Rev       Date:  2018-06-18       Impact factor: 12.111

6.  Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?

Authors:  Sven Otto; Matthias Tröltzsch; Vesna Jambrovic; Sappasith Panya; Florian Probst; Oliver Ristow; Michael Ehrenfeld; Christoph Pautke
Journal:  J Craniomaxillofac Surg       Date:  2015-04-10       Impact factor: 2.078

7.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

8.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

Review 9.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.